Initial AX-0810 data show no safety signals after 4 weeks of dosing and pharmacokinetics consistent with non-clinical data; ...
Ascidian Therapeutics ("Ascidian"), a biotechnology company seeking to treat human diseases by rewriting RNA, and Forge ...
The most recent developments in the field of A-to-I RNA modification, with a special emphasis on the roles of A-to-I in the genesis and progression of cancer. Adenosine-to-inosine (A-to-I) RNA editing ...
Treating acute myeloid leukemia (AML) depends on knowing what goes wrong inside cells. A new study suggests that two genetic ...
New research provides a mechanistic map of how genetic mutations disrupt RNA splicing in acute myeloid leukemia.
The research explores how CRISPR can be used to edit RNA. A team at Montana State University published research that shows how RNA, the close chemical cousin to DNA, can be edited using CRISPRs. The ...
AZoLifeSciences on MSN
Synthetic RNA platform converts viral replication into detectable cellular signals
The technology, called the Viral-Engineered RNA-based Activation System (VERAS), hijacks the virus's own replication ...
The technology, called the Viral-Engineered RNA-based Activation System (VERAS), hijacks the virus's own replication ...
ProQR Therapeutics is advancing its Axiomer ADAR-mediated RNA editing pipeline, aiming to file a Clinical Trial Application for its lead program AX-0810, targeting NTCP for cholestatic diseases, by Q2 ...
In a paper published on aBIOTECH, the authors investigated the off-target effects of ADAR-mediated RNA editing in rice ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback